Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

Eva C. Guinan, MD

  • Physician
  • Professor of Radiation Oncology, Harvard Medical School

Appointment Phone

  • 888-733-4662 (New Pediatric Patients)
  • 617-632-3270 (Established Pediatric Patients)


Treatment Centers


Clinical Interests

Aplastic anemia, Bone marrow failure disorders, Hematopoietic stem cell transplantation, Myelodysplasia, Regimen-related toxicity



Board Certifications

  • Pediatric Hematology/Oncology, 2004
  • Pediatrics, 1986


  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology


  • Boston Children's Hospital


  • Boston Children's Hospital

Medical School

  • Harvard Medical School, 1980


Dr. Guinan received her MD from Harvard Medical School in 1980, followed by a pediatric residency at Children's Hospital and a pediatric hematology-oncology fellowship at Children's Hospital and DFCI. She was appointed associate director of the Bone Marrow Transplant Service in 1990 and directed the program from 1997 through 2005. She assumed a new position in 2005 as the Associate Director of the Center for Clinical and Translational Research. Her own translational research program focuses on the costimulatory blockade as a mechanism of overcoming problems related to allogenicity in transplantation and the amelioration of regimen-related toxicity.


Induction of Anergy by Costimulatory Blockade

Our research focuses on overcoming problems related to allogenicity in transplantation. Allogeneic transplantation is limited, in large part, by the ability to find donors of suitable histocompatibility. Global immunosuppression has been an incomplete and highly toxic approach to this problem. Current understanding of T cell activation suggests that blocking B7-CD28 interactions of the costimulatory pathway for human T helper cells may provide both antigen-specific T cell hyporesponsiveness and active suppression of alloantigen specific immunity. We are applying these various strategies to the transplant setting and investigating other approaches to improve immunity after transplantation. Another area of active investigation is the mitigation of regimen-related toxicity during transplantation and/or chemotherapy. We are investigating novel agents for prevention or treatment of regimen-related toxicity, with a focus on mitigating radiation toxicity. In another area of investigation, we are examining the role of distributed problem-solving techniques in generating, evaluating and maintaining innovation in healthcare related research.